SLE medication list

An SLE medication list is a clinical record of every drug a patient with systemic lupus erythematosus (SLE) takes, grouped by class. Each entry carries the dose, indication, monitoring schedule, and review date. The free template below gives rheumatologists, internists, and primary care physicians a ready-made table for tracking lupus therapy at every visit.

SLE treatment draws on five drug groups. Hydroxychloroquine is the backbone, NSAIDs relieve symptoms, and corticosteroids control flares. Conventional immunosuppressants such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide spare patients from long-term steroids. Refractory disease calls for newer targeted therapy, meaning the biologics belimumab and anifrolumab, or voclosporin, an oral calcineurin inhibitor for lupus nephritis.

Each of those drugs brings its own monitoring task, from retinal exams to blood counts. That makes the list the patient’s safety schedule as much as a record of what they take.

Key takeaways

An SLE medication list records every lupus drug a patient takes, grouped by class with its dose, indication, monitoring, and review date.

Hydroxychloroquine is the foundation of SLE therapy for every patient without a contraindication, with NSAIDs for pain and corticosteroids for flares.

Conventional immunosuppressants and the biologics belimumab and anifrolumab treat moderate-to-severe disease. Voclosporin, an oral calcineurin inhibitor, treats active lupus nephritis.

Keep hydroxychloroquine at or below 5 mg/kg/day of real body weight, with retinal exams at baseline and then annually.

Practice management software like Pabau keeps the list in the patient record and sends recall reminders, so lab work and eye exams stay on schedule.

What is an SLE medication list and why does your practice need one?

An SLE medication list captures every medication a lupus patient receives, alongside dose, frequency, indication, monitoring requirements, and contraindications. A pharmacy list stops at the drug and the dose. This list adds the safety and efficacy checks a rheumatologist runs at each visit.

SLE treatment is long-term and usually involves several drugs at once. Hydroxychloroquine prevents flares and organ damage over years. Corticosteroids suppress acute inflammation, and immunosuppressants spare patients from cumulative steroid toxicity. Biologics target specific immune pathways in refractory disease.

Each drug carries its own monitoring burden, such as retinal exams for hydroxychloroquine or bone protection for steroids. A structured list keeps those checks on schedule and leaves a defensible audit trail. The ladder below shows which check each treatment step adds.

How to use the template at each visit

The downloadable template is organized by drug class, with column headers for drug name, brand name, strength, route, frequency, indication, and monitoring schedule. The same layout works for an RA medication list, so rheumatoid arthritis and lupus patients share one documentation format. Use these five steps to put it to work.

1. Print or digitize the template. Use the PDF as a paper form for consultation notes. Or import its table into your digital intake forms so medications are captured electronically at each visit.
2. Complete the table at diagnosis or at a medication review. List every current medication with its dose and start date, whether that’s hydroxychloroquine, prednisone, an NSAID, or an immunosuppressant. Note the indication, for example “maintenance therapy,” “flare management,” or “nephritis induction.”
3. Add monitoring checkpoints for each drug. Record when the patient is due for retinal screening (hydroxychloroquine), a bone density scan (long-term steroids), or a blood panel (immunosuppressants). Flag each date in your recall system so none slips.
4. Review and update the list at every visit. Mark new medications, dose changes, and stops. Note clinical response and any adverse events, then adjust the monitoring schedule to the treatment intensity.
5. Connect it to the patient record. Use Pabau’s medical records to link the list to progress notes, treatment plans, and lab results. The result is one medication timeline that stays accessible and audit-ready.

First-line SLE treatment: Hydroxychloroquine and NSAIDs

Hydroxychloroquine (Plaquenil) is the cornerstone of SLE therapy. Rheumatology guidelines recommend it for every SLE patient without a contraindication, at 200–400 mg daily. It prevents flares, reduces organ damage, and improves long-term survival.

Keep the daily dose at or below 5 mg/kg of real body weight to limit the risk of retinal toxicity. NSAIDs such as ibuprofen and naproxen ease pain, arthralgia, and mild inflammation. They carry kidney and gastrointestinal risks in SLE, especially in lupus nephritis.

Corticosteroids for SLE flare management

Prednisone and methylprednisolone are standard flare therapy. Acute flares are treated with prednisone 0.5–1 mg/kg/day (typically 20–60 mg daily), tapered over 4–12 weeks as disease activity improves. IV methylprednisolone 500–1,000 mg daily for three days is reserved for severe, organ-threatening flares, such as CNS lupus or severe nephritis.

Every patient on long-term corticosteroids needs bone protection. That means calcium 1,200 mg daily and vitamin D 800–1,000 IU daily. Add alendronate 70 mg weekly if the prednisone dose exceeds 7.5 mg daily for more than three months.

Conventional immunosuppressants: DMARDs for SLE

Mycophenolate mofetil (MMF, CellCept) is first-line induction and maintenance therapy for lupus nephritis, with large RCT evidence showing superior outcomes to cyclophosphamide. Typical dosing is 1–3 g daily in divided doses. Azathioprine (Imuran) 1–2.5 mg/kg daily is a traditional steroid-sparing agent.

Methotrexate 7.5–20 mg weekly treats non-renal SLE. Cyclophosphamide (Cytoxan) IV pulse 500–1,000 mg monthly for six months is reserved for severe lupus nephritis or life-threatening CNS lupus, given its toxicity.

All conventional immunosuppressants need regular lab monitoring. Order a complete blood count (CBC) and comprehensive metabolic panel every 4–8 weeks during induction, then every three months on maintenance. Keeping lab orders and results in the same system as the medication list makes an overdue panel easy to spot.

Methotrexate and cyclophosphamide are contraindicated in pregnancy. Women of childbearing age on either drug need reliable contraception and counseling on teratogenic risk.

Biologics and other newer FDA-approved therapies

Belimumab (Benlysta) is a B-lymphocyte stimulator inhibitor, approved in 2011 for moderate-to-severe SLE. It is given IV at 10 mg/kg at weeks 0, 2, and 4, then monthly, or as 200 mg SC weekly.

Anifrolumab (Saphnelo), approved on July 30, 2021, is a type I interferon receptor antagonist given IV at 300 mg monthly. TULIP trial data showed significant improvement in moderate-to-severe SLE refractory to standard therapy.

Voclosporin (Lupkynis), approved in January 2021, is an oral small-molecule calcineurin inhibitor for active lupus nephritis. Unlike belimumab and anifrolumab, it is not a biologic. The dose is 23.7 mg twice daily, adjusted for kidney function.

Biologics are usually reserved for moderate-to-severe disease, refractory SLE, or lupus nephritis that conventional immunosuppressants haven’t controlled. Screen for tuberculosis and hepatitis B and C before starting one. Live vaccines are contraindicated during biologic therapy.

Medications that cause drug-induced lupus (DILE)

Drug-induced lupus erythematosus (DILE) is a distinct syndrome triggered by certain medications. Procainamide, hydralazine, isoniazid, minocycline, and TNF inhibitors carry the highest risk. Unlike SLE, it typically resolves once the offending drug is stopped.

When prescribing for SLE patients, avoid known DILE culprits where possible. If one is necessary, use the lowest effective dose and watch closely for symptom flares. These are the drugs most often implicated.

• Procainamide (antiarrhythmic) and hydralazine (antihypertensive)
• Isoniazid and rifampin (tuberculosis drugs)
• Minocycline (antibiotic)
• TNF inhibitors such as adalimumab and infliximab
• Sulfonamides and certain phenothiazines

Quick monitoring reference by drug class

Every drug used in SLE carries its own monitoring requirements. Use this reference at review visits to confirm that no test is overdue.

Automated workflow alerts can flag when a monitoring test is due, so staff don’t have to track dates by hand.

Managing lupus-related fatigue: Medication approaches

Fatigue is the most common symptom in SLE, and it often persists after inflammation is controlled. Optimize hydroxychloroquine dosing first. Some patients benefit from DHEA 200 mg daily, although the evidence is modest.

Patient education on sleep hygiene, exercise, and stress management matters as much as the medication. Screen for depression and hypothyroidism, which both amplify fatigue. Avoid unnecessary polypharmacy, since a simpler regimen sometimes improves energy and adherence.

Bone protection and supportive medications

Long-term corticosteroid therapy accelerates bone loss. Every patient on prednisone above 7.5 mg daily for more than three months needs alendronate 70 mg weekly or risedronate 35 mg weekly. Add calcium carbonate 1,200 mg daily in divided doses and vitamin D 800–1,000 IU daily.

Proton pump inhibitors at 20–40 mg daily protect the stomach in patients on chronic NSAIDs or corticosteroids. A baseline DXA scan is standard for all women on long-term steroids and recommended for men over 50.

How Pabau keeps SLE medication lists and monitoring on schedule

Many rheumatology practices track lupus medications across paper lists, lab portals, and a separate reminder system. A dose change gets written in one place, while the next retinal exam date sits in another.

Practice management software like Pabau brings those pieces into one patient record. The medication list sits alongside progress notes, treatment plans, and lab results. Digital forms capture the regimen before the visit, and automated reminders go out when a monitoring test is due.

Clinicians see the full regimen before each consultation, and every change is documented for audit. Book a demo with Pabau to see how it fits your rheumatology team’s workflow.

Keep every lupus medication check on schedule

Pabau stores the SLE medication list in the patient record and sends automated reminders for lab work and eye exams. Your team spends less time chasing monitoring dates.

Book a demo

Conclusion

Lupus therapy rarely stays still. Doses taper, drugs are added for flares, and each change brings a new monitoring date. A medication list protects the patient when it’s updated at every visit and every dose change.

Start with the patients on the most drugs, such as those with lupus nephritis on an immunosuppressant plus a biologic. Their lists carry the most monitoring dates and the highest cost of a missed one. The trade-off is time, since a thorough first entry takes a full chart review.

Once the list lives in the patient record, recall dates can run automatically. Book a demo to see how Pabau tracks lupus medications and monitoring for your practice.

Continue your research

Treating rheumatoid arthritis too? RA medication list applies the same drug-class layout to rheumatoid arthritis therapy.

Need a dosing timetable for patients? Medication schedule template sets out what to take and when, in a printable form.

Want a record of each dose given? Medication log template shows what to record for each medication.

Checking a drug before prescribing? Drug card template condenses a drug’s key facts for nurses and clinicians.

Keeping dispensing records? Pharmacy record template covers what to include and how long to keep it.

Frequently asked questions